New blood test could spot multiple cancers before symptoms appear
NCT ID NCT03869814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2018
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Both study groups enrolled at medical centers across the United States
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Subjects must be between 21-80 years of age at the time of enrollment 2. Patient fully consented 3. Cancer diagnosis OR high clinical suspicion for cancer, based on the participating site's and practitioner's standards of care (SOC) 4. No previous history of cancer and treatment naïve at time of enrollment Exclusion Criteria 1. Age \< 21 OR \> 80 years of age 2. Any prior cancer diagnosis with or without treatment (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment) 3. Receipt of any cancer therapy including chemotherapy, radiation, palliative radiation, hormonal or naturopathic therapies 4. In situ carcinoma without an invasive component 5. Any surgery requiring general anesthesia within 2 months of collection. Anesthesia used in procedures such as colonoscopy and EBUS is acceptable. 6. Receipt of systemic immunomodulation therapy within past 12 months 7. Currently pregnant, or pregnancy within last 12 months 8. Organ transplantation 9. Received dialysis 10. Blood transfusion within 1 month 11. Known HIV/AIDs, Hepatitis A, D, or E, TB, any kind of prion disorder (e.g., CJD) or other infectious pathogens currently present or present in past 5 years.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diagnosis of cancer of various organs are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ClearNote Health, Inc.
RECRUITINGSan Diego, California, 92121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A single arm, open label, dose-escalation phase i and dose-expansion phase IIa clinical study to evaluate the feasibility, safety, and efficacy of allogeneic chimeric antigen receptor (CAR) Gamma-Delta t cells CAR001 in subjects with Relapsed/Refractory solid tumors
- Can an antidepressant calm Chemotherapy's nerve pain?
- A new imaging agent aims to make solid tumors visible on PET scans
- Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?
- Can a platform trial match the right drug combo to each tumor?
- Can immune cell infusions help fight solid tumors?